Are x-linked inhibitor of apoptosis single nucleotide polymorphisms and copy number variation risk factors for asthma?
There is no evidence of CNV in BIRC4, and BIRC4 is not a susceptibility gene for asthma.
Given the limited global availability of lopinavir/ritonavir, its significant formulation challenges in young children, and the significant paediatric treatment gap, tablet fixed-dose-combination NVP-based ART remains a good alternative to syrup lopinavir-based ART for children, particularly those over 1 year and even if exposed to sdNVP.